ARCELLX INC (ACLX) Stock Price, Forecast & Analysis
NASDAQ:ACLX • US03940C1009
ACLX Key Statistics, Chart & Performance
The current stock price of ACLX is 113.82 USD. In the past month the price increased by 68.02%. In the past year, price increased by 75.49%.
ACLX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ACLX. When comparing the yearly performance of all stocks, ACLX is one of the better performing stocks in the market, outperforming 94.26% of all stocks.
ACLX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACLX. ACLX has a great financial health rating, but its profitability evaluates not so good.
ACLX Financial Highlights
Over the last trailing twelve months ACLX reported a non-GAAP Earnings per Share(EPS) of -3.93. The EPS decreased by -453.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.21% | ||
| ROE | -49.42% | ||
| Debt/Equity | 0 |
ACLX Forecast & Estimates
26 analysts have analysed ACLX and the average price target is 114.6 USD. This implies a price increase of 0.69% is expected in the next year compared to the current price of 113.82.
For the next year, analysts expect an EPS growth of -107.18% and a revenue growth -73.06% for ACLX
ACLX Ownership
ACLX Latest News, Press Relases and Analysis
ACLX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 405.578B | ||
| AMGN | AMGEN INC | 16.85 | 204.31B | ||
| GILD | GILEAD SCIENCES INC | 16.5 | 185.891B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.58 | 122.042B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 83.206B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.54 | 43.51B | ||
| INSM | INSMED INC | N/A | 33.916B | ||
| NTRA | NATERA INC | N/A | 29.129B | ||
| BIIB | BIOGEN INC | 12.86 | 28.815B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.84 | 20.433B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACLX
Company Profile
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Redwood City, California and currently employs 163 full-time employees. The company went IPO on 2022-02-04. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. The company is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Company Info
ARCELLX INC
800 Bridge Parkway
Redwood City CALIFORNIA US
Employees: 163
Phone: 12403270603
ARCELLX INC / ACLX FAQ
What does ACLX do?
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Redwood City, California and currently employs 163 full-time employees. The company went IPO on 2022-02-04. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. The company is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
What is the current price of ACLX stock?
The current stock price of ACLX is 113.82 USD. The price increased by 0.06% in the last trading session.
What is the dividend status of ARCELLX INC?
ACLX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACLX stock?
ACLX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is ARCELLX INC (ACLX) stock traded?
ACLX stock is listed on the Nasdaq exchange.
Can you provide the market cap for ARCELLX INC?
ARCELLX INC (ACLX) has a market capitalization of 6.58B USD. This makes ACLX a Mid Cap stock.